

Curriculum Vitae

Jessica Watson, CCRC

Research Affiliation

Elligo Health Research, Inc., 2022- Present
11612 Bee Cave Road, Bldg. 1, Suites 100 & 150, Austin, TX 78738


Research Affiliation

Arkansas Center for Sleep Medicine, PLLC
11219 Financial Centre Parkway, Suite 101
Little Rock, AR 72211
(501) 553-9987 x106
(501) 553-9986 FAX

Research Affiliation

Preferred Research Partners, Inc.
11219 Financial Centre Parkway, Suite 320
Little Rock, AR 72211
(501) 553-9987 x106
(501) 553-9986 FAX

Signature: _____



Date: _____

22 AUG 2022

Jessica Watson
jwatson@preferredresearchpartners.com
501-553-9987 x.106

Office:

Paul E. Wylie, M.D., P.A. (Clinic Office)
11219 Financial Center Parkway, Suite 315
Little Rock, AR 72211
Phone: 501-661-9191 x.106 Fax: 501-661-1991

Arkansas Center for Sleep Medicine, PLLC (Polysomnography Lab)
11219 Financial Center Parkway, Suite 101
Little Rock, AR 72211
Phone: 501-661-9191 x.106 Fax: 501-661-1991

Preferred Research Partners, Inc.
11219 Financial Centre Parkway, Suite 320
Little Rock, AR 72211
Phone: 501-553-9987 x.106 Fax: 501-553-9986

Education: **Arkansas State University-Beebe**
 Pulaski Technical College
 Associate of Applied Science in Business Technology with
 emphasis in Legal Assistant
 Graduation Date: May 2010
 3.65 GPA

Work Experience: **Preferred Research Partners, Inc., Little Rock, AR**
 August 2012 - present
 Clinical Research Coordinator
 Position involves conducting study visits & ensuring patient safety,
 AE/SAE reporting, facilitating informed consent process, collection
 of IRB correspondence, patient recruitment, CRF and source
 documentation completion, laboratory collection and processing.

Research Experience:

- **2012: UCB, Restless Legs Syndrome in Adolescents – SP1004**
- **2012: Bristol Myers Squibb, Type II Diabetes & Hypertension – MB102073**
- **2012: Synergy Pharmaceuticals, Chronic Idiopathic Constipation – SP304-20210**
- **2012: UCB, Restless Legs Syndrome in Adolescents – SP1005**
- **2012: Bristol Myers Squibb, Type II Diabetes & Hypertension – MB102077**

- 2012: Forest Research Institute, Hypertension – NAC-MD-01
- 2012: Ardea, Gout – RDEA594-301
- 2012: Orexigen, Obesity – NB-CVOT
- 2012: Novartis, High Triglycerides – CLCQ908C2201
- 2012: Furiex Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – 27018966IBS3001
- 2012: Lexicon Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – LX1033-1.201
- 2012: Tioga Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – ASMP3001
- 2012: Shiongi, Inc., Opioid Induced Constipation – 1107V9221
- 2012: Tsumura Pharmaceuticals, Crohn's Disease – TU100P2T2
- 2012: Coronado Biosciences, Crohn's Disease – CNDO-201-003
- 2012: Shire, GERD – SPD557-206
- 2012: UCB, Healthy Adult, Phase I – SP1031
- 2012: UCB, Restless Legs Syndrome – RL0003
- 2012: GSK, Restless Legs Syndrome – RXP114025
- 2013: Ardea BioSciences, Gout – RDEA594-306
- 2013: Dr. Reddy's Laboratories, Chronic Idiopathic Constipation – DRL-USG01-L/2012
- 2013: Purdue Pharma L.P., Chronic Low Back Pain & Opioid-Induced Constipation – ONU3705
- 2013: Cubist Pharmaceuticals, Opioid-induced Constipation – 5945-SOIC-12-05
- 2013: Cubist Pharmaceuticals, Opioid-induced Constipation – 5945-OIC-12-04
- 2013: Ferring International Pharmascience Center US, Inc., Chronic Idiopathic Constipation – 000080
- 2013: Ferring International Pharmascience Center US, Inc., Chronic Idiopathic Constipation – 000081
- 2013: Synergy Pharmaceuticals, Inc., Chronic Idiopathic Constipation (OLE CIC) – SP304203-01
- 2013: Shiongi, Inc., Opioid Induced Constipation – 1315V9232
- 2013: Menarini, Diarrhea-Predominant Irritable Bowel Syndrome – NAK-07
- 2013: Synergy Pharmaceuticals, Inc., Chronic Idiopathic Constipation (CIC3) – SP304203-00
- 2014: Evoke, Diabetic Gastroparesis – METO-IN-003
- 2014: Evoke, Diabetic Gastroparesis – METO-IN-004
- 2014: Eisai, Long-Term incidence of MACE events & conversion to Type II Diabetes Mellitus in Obese & Overweight Subjects with Cardiovascular Disease or Multiple CV Risk Factors – APD356-G000-401
- 2014: A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects with Gout – Takeda Development Center Americas, Inc. – FEB-XR_301

- 2014: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn's Disease – Salix Pharmaceuticals, Inc. – RECD3125
- 2014: A Randomized Double-Blind, Placebo Controlled, Flexible and Fixed Dose, Parallel Group Study of Extended-Release Lorazepam (EDG004) for the Treatment of Generalized Anxiety Disorder (GAD) – Edgemont Pharmaceuticals – EDG004-003
- 2014: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Assess The Effects Of TC-6499 on Gastric Emptying Time In Diabetic Subjects with Gastroparesis – Targacept – TC-6499-12-CLP-005
- 2014: Xenon, RLS Genetic Biomarker – XEN-RLS
- 2015: Rhythm Pharmaceuticals, Diabetic Gastroparesis – RM-131-009
- 2015: Jazz Pharmaceuticals, Narcolepsy & Excessive Daytime Sleepiness – 14-002
- 2015: Jazz Pharmaceuticals, Obstructive Sleep Apnea & Excessive Daytime Sleepiness – 14-003
- 2015: Jazz Pharmaceuticals, Long-term extension study for Obstructive Sleep Apnea or Narcolepsy with Excessive Daytime Sleepiness – 14-005
- 2015: Neurocrine Biosciences, Inc., Tardive Dyskinesia – NBI-98854-1304 (KINECT3)
- 2015: Theravance, Diabetic or Idiopathic Gastroparesis – 0099
- 2015: Synergy Pharmaceuticals, Inc., Irritable Bowel Syndrome-Constipation – SP304203-04
- 2015: Forest Research Institute, Inc., Irritable Bowel Syndrome-Constipation &/or Chronic Idiopathic Constipation – LIN-MD-10
- 2015: Janssen Research & Development, Treatment-resistant Depression – ESKETINTRD3001 (TRANSFORM-1)
- 2015: Janssen Research & Development, Treatment-resistant Depression – ESKETINTRD3003 (SUSTAIN-1)
- 2015: Neurocrine Biosciences, Inc., Tardive Dyskinesia – NBI-98854-1402 (KINECT4)
- 2015: Naurex Inc., Major Depressive Disorder – NRX1074-C-202
- 2015: Gilead, Ulcerative Colitis – GS-US-326-1100
- 2015: Sunovion Pharmaceuticals, Adult Attention Deficit Hyperactivity Disorder (ADHD) – SEP360-301
- 2015: Ardelyx – IBS-C – TEN-01-301
- 2016: Akili Interactive Labs, Inc. - A study to assess the feasibility of and to characterize Project: EVO Monitor game-play cognitive function measurements

when played daily, weekly, or multiple times per day in adults 40-55 years old (Akili-026)

- 2016: Ferring International Pharmascience Center US, Inc., Ulcerative Colitis – 000174
- 2016: Ferring International Pharmascience Center US, Inc., Ulcerative Colitis – 000175
- 2016: Conatus Pharmaceuticals, Non-alcoholic Steatohepatitis (NASH) – IDN-6556-12
- 2016: Synergy Pharmaceuticals, Irritable Bowel Syndrome with Constipation (IBS-C) – SP304203-06
- 2016: Janssen Research & Development, Treatment-resistant Depression – ESKETINTRD3008
- 2016: Eisai Pharmaceuticals, Elderly Insomnia – E2006-G000-304
- 2016: Luitpold Pharmaceuticals, Inc., Restless Legs Syndrome – 1VIT14037
- 2016: Braintree Laboratories, Chronic Constipation – BLI400-302
- 2016: Braintree Laboratories, Opioid Induced Constipation – BLI801-203
- 2016: Applied Proteomics – Colorectal Cancer Screening – API-CP001
- 2017: Takeda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – TAK906-1002
- 2017: Conatus Pharmaceuticals – Non-Alcoholic Cirrhosis – IDN-6556-17
- 2017: Shire Pharmaceuticals – Preschooler ADHD – SPD489-347
- 2017: Shire Pharmaceuticals – Preschooler ADHD – SPD489-348
- 2017: Allergan – Diabetic Gastroparesis – RLM-MD-01
- 2017: Braintree Laboratories, Bowel Prep for Colonoscopy – BLI4700-302
- 2017: Tonix Pharmaceuticals, Military-Related PTSD – TNX-CY-P301
- 2017: Vanda Pharmaceuticals, Inc. – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-2301
- 2017: Janssen – Major Depressive Disorder – CNT0136MDD2001
- 2017: Allergan – Pediatric Major Depressive Disorder – LVM-MD-11
- 2017: Allergan – Diabetic Gastroparesis – RLM-MD-04
- 2018: Freenome Holdings, Inc., Health Decisions – Colorectal Cancer Screening – FRE-001
- 2018: Allergan – Diabetic Gastroparesis – RLM-MD-03
- 2018: Tonix Pharmaceuticals, Military-Related PTSD – TNX-CY-P303
- 2018: Janssen Research & Development, Insomnia – 42847922ISM2005
- 2018: Shire Pharmaceuticals – Preschooler ADHD PK – SHP465-112
- 2018: Shire Pharmaceuticals – Adolescent ADHD – SHP465-308
- 2018: Shire Pharmaceuticals – Adolescent ADHD – SHP465-309
- 2018: AbbVie – Testosterone Replacement Therapy for Hypogonadism – M16-100
- 2018: Otsuka Pharmaceuticals – Post Traumatic Stress Disorder – 331-201-00061
- 2018: Idorsia Pharmaceuticals – Insomnia – ID-078A301
- 2018: Idorsia Pharmaceuticals – Insomnia – ID-078A303
- 2018: Janssen Research & Development – Major Depressive Disorder – 67953964MDD2001

- 2018: Neos Therapeutics – Attention Deficit Disorder in Children 4-6 y/o – NT0202.1009
- 2018: Neos Therapeutics – Attention Deficit Disorder in Children 4-6 y/o – NT0202.1010
- 2018: Tonix Pharmaceuticals - Military-Related PTSD – TNX-CY-P306
- 2018: Allergan – Diabetic Gastroparesis – 3071-305-020
- 2018: Ironwood Pharmaceuticals – GERD – C3718-302
- 2019: Tonix Pharmaceuticals - PTSD – TNX-CY-P302
- 2019: Apnimed – Obstructive Sleep Apnea – APN-002
- 2019: Aptinyx – Post-Traumatic Stress Disorder – NYX-783-2004
- 2019: Axsome Pharmaceuticals – Treatment-Resistant Depression – AXS05-301
- 2019: Biohaven Pharmaceuticals – Obsessive Compulsive Disorder – BHV4157-202
- 2019: Otsuka Pharmaceuticals – Post Traumatic Stress Disorder – 331-201-00071
- 2019: Takeda – Obstructive Sleep Apnea – Phase 1 – TAK-925-2001
- 2019: LG Chem – Gout with Hyperuricemia – LG-GDCL002
- 2019: Applied Therapeutics - Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure) – AT-001-2001
- 2019: Adare Pharmaceuticals – Eosinophilic Erosive Esophagitis – SP-1011-003
- 2019: Allergan - Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis – 3152-301-002
- 2019: Allergan – Constipation in Children 6-17 y/o – LIN-MD-64
- 2019: Allergan – Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C) – LIN-MD-66
- 2019: Allergan - Pediatric Participants (Age 2 to 5 Years) with Functional Constipation – LIN-MD-67
- 2019: Braintree Laboratories - Bowel Prep for Colonoscopy – BLI4900-302
- 2019: Phathom Pharmaceuticals – Erosive Esophagitis – EE-301
- 2019: Phathom Pharmaceuticals – H. Pylori – HP-301
- 2019: Vanda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-3301
- 2019: Vibrant Ltd – Chronic Idiopathic Constipation – V270
- 2020: Takeda – Idiopathic Hypersomnia – Phase 1 – TAK-925-2002
- 2020: Neurogastrx – Diabetic or Idiopathic Gastroparesis – NG101-201
- 2020: Allergan – Major Depressive Disorder – 2006-308-008
- 2020: Otsuka – Pediatric Attention Deficit Hyperactivity Disorder – 405-201-00010
- 2020: Apnimed – Obstructive Sleep Apnea – APN-006
- 2019: Guardant Health - Evaluation of ctDNA LUNAR-2 Assay in an Average Patient Screening Episode – 02-GI-002

•
Training Documentation:

May 2020: American Heart Association Basic Life Support (CPR and AED) Program

May 2020: Otsuka GCP ICH E6 training

September 2019: Stericycle Biohazardous Waste Training

September 2019: Stericycle DOT Hazardous Materials Training

September 2019: Stericycle Blood Bourne Pathogen Training

January 2019: GCP ICH E6 training

September 2018: GCP ICH E6 training

May 2018: American Red Cross, Adult and Pediatric First Aid/CPR/AED

August 2017: Stericycle Biohazardous Waste Training

August 2017: Stericycle DOT Hazardous Materials Training

August 2017: Stericycle Blood Bourne Pathogen Training

May 2017: GCP ICH E6 training

January 2016: IATA training

April 2015: CITI Program, Human Subjects Research Basics

September 2014: IATA training

July 2014: National Institutes of Health web-based training on "Protecting Human Research Participants"

March 2014: Stericycle Biohazardous Waste Training

March 2014: Stericycle DOT Hazardous Materials Training

October 2013: Stericycle Blood Bourne Pathogen Training

September 2012: National Institutes of Health web-based training on "Protecting Human Research Participants"

September 2012: IATA training

September 2012: GCP Manual/Code of Federal Regulations Review
Phlebotomy Training

Informed Consent Training
Vital Signs Training
EKG Training
Coordinator Training
Job Shadowing
Blood Borne Pathogen Training
CRF Training
SOP Review
Lab Processing Training
HIPAA Training